

FUND OBJECTIVE

To achieve long term capital growth through investment in a relatively concentrated, actively managed portfolio of global equity securities issued by companies with a high overall positive impact on society.

INVESTMENT STRATEGY & APPROACH

Please refer to the Master Fund Fact Sheets at <https://www.sunlifemalaysia.com/insurance-and-takaful/investment-linked-fund/yearly-fund-fact-sheet/> for more information on the Investment Strategy and Approach for the target fund.

FUND DETAILS

Launch Date	21 July 2021	Domicile	Malaysia
Currency	Ringgit Malaysia	Launch Price	RM1.0000
Units in Circulation	8.82 million units (29 August 2025)	Fund Size	RM10.33 million (29 August 2025)
Unit NAV	RM1.1719 (29 August 2025)	Target Fund	Nomura Global Sustainable Equity Fund - MYR Class B
Fund Manager	Nomura Asset Management Malaysia Sdn Bhd	Taxation	8% of annual investment income
Performance Benchmark	MSCI All Country World Index	Frequency and Basis of Unit Valuation	The unit price is determined daily based on value of the holdings in the target fund, net of expenses, divided by the total number of units in that fund
Target Market	Suitable for investors: - are seeking long term capital growth - want a portfolio of investments that provides positive impact on the sustainable development of society - want to have portfolio with global exposure - are prepared to accept moderate level of volatility	Fund Management Charge	Sun Life Malaysia does not impose any fund management charge on Sun Life Malaysia Global Sustainable Fund

ASSET ALLOCATION OF THE TARGET FUND

Master fund	Deposits, money market instruments and / or held in cash
Minimum of 85% Net Asset Value (NAV)	Maximum of 15% of NAV

SECTOR ALLOCATION OF THE TARGET FUND

Information Technology	22.56%
Industrials	21.96%
Health Care	21.64%
Financials	19.63%
Utilities	6.58%
Communication Services	3.95%
Cash & Others	3.68%
Total	100.00%

TOP HOLDINGS OF THE TARGET FUND

Microsoft Corporation	5.84%
Alphabet Inc. Class A	3.95%
Mastercard Incorporated Class A	3.64%
Taiwan Semiconductor Manufacturing Co.	3.59%
Broadcom Inc.	3.49%

PERFORMANCE RECORD

This fund feeds into Nomura Global Sustainable Equity Fund - MYR Class B ("target fund") with the objective to achieve long-term capital growth through investment in a relatively concentrated, actively managed portfolio of global equity securities issued by companies with a high overall positive impact on society.

Table below shows the investment returns of Sun Life Malaysia Global Sustainable Fund versus its benchmark as at 29 August 2025:

%	YTD	1M	3M	6M	1-Year	3-Years	Since Inception
Fund*	2.17	-0.41	2.50	0.83	0.96	28.39	17.19
Benchmark	6.87	1.40	7.39	4.40	11.57	46.52	34.42

* Calculation of past performance is based on NAV-to-NAV

Table below shows the historical performance of the underlying collective investment schemes (CIS) for calendar year returns:

(%)	2024	2023	2022
Target Fund	7.97	19.74	-13.45

Source: Refinitiv Lipper

FUND MANAGER'S COMMENTS

MYR Class B returned -0.41% in August underperforming the MSCI ACWI by 200 bps. During the month of August, the Fund registered a negative allocation headwind (c.50 bps) as a result of the underperformance of Industrials and the outperformance of Consumer Discretionary. Selection was negative through the month with Financials and Information Technology detracting slightly offset by positive selection in Healthcare. The backdrop has remained favourable for global equities with the rally through the month of August culminating in new YTD highs for the MSCI ACWI. Discussions around the Fed cutting interest rates have intensified as US jobs data out in early August revised down the previous 2 months' numbers by 258k indicating a potential softening in the labour market whilst the Trump administration have continued to be vocal in their support for cuts. The prospect of looser monetary policy combined with strong earnings growth (particularly in Information Technology) continues to drive optimism amongst investors.

The greatest contributors to performance in August were Alphabet (+11%) and AbbVie (+11%). We think investors are growing more comfortable with Alphabet's positioning in generative AI after considerable debate during the last 2 years on whether it is an AI 'winner or 'loser.' AbbVie delivered strong 2Q results with the immunology portfolio (led by Skyrizi) continuing to outperform investor expectations. Investors continue to see the name as a resilient option in pharmaceuticals with the shares performing well in August on the back of this update.

The two biggest detractors were not holding Apple (+12%) and Schneider (-6%). After a tough start to the year, Apple has benefited from a stabilising tariff environment, hope for the company's ability to incorporate AI into its hardware, and growing focus on the upcoming product cycle. The shares appreciated in August with this move taking away from the fund's performance. Schneider declined in August despite an inline H1 print. We think the market reacted negatively due to concerns over pricing and the gross margin. Results were also somewhat lacklustre relative to other electrical peers raising questions for investors. Management did reiterate FY guidance and while there is some catch up to do in H2, we expect the group to deliver meaningful progress through the rest of the year

Impact Focus of the Month:

Towards the end of August, we initiated a position in Edwards Lifesciences. The California-based company was founded in 1958 by Miles Edwards, an electrical engineer who invented the first artificial heart valve. Since then, the company has become a strong force in cardiology medtech and has developed the leading position in the TAVR market. A device that tackles aortic stenosis without requiring open heart surgery. From a sustainability perspective, we think the group has a particularly strong impact on improving health outcomes through its commercial business but we are also encouraged by its philanthropic efforts with Every Heartbeat Matters, the group's corporate charity, on track to impact 2.5mn underserved patients by the end of 2025. From a financial perspective, Edwards Lifesciences is quite differentiated in medtech for balancing strong margins (>25% EBIT margin) with a strong willingness to reinvest in R&D. Over time that combination has resulted in strong ROIC and shareholder returns, which sets it apart from many healthcare peers.

RISKS

All investment carries some form of risks. The potential key risks include but are not limited to the following:

Returns not guaranteed	The investment of the fund is subject to market fluctuations and its inherent risk. There is NO GUARANTEE on the investment returns, nor any assurance that the target fund’s investment objective will be achieved.
Market risk	The value of an investment will decrease or increase due to changes in market factors i.e. economic, political or other events that impact large portions of the market. Market risk cannot be eliminated, hence the target fund’s investment portfolio may be prone to changing market conditions that may result in uncertainties and fluctuations in the value of the underlying of the target fund’s investment portfolio, causing the NAV or prices of units to fluctuate.
Inflation risk	This is the risk that your investment in the target fund may not grow or generate income at a rate that keeps pace with inflation. This would reduce your purchasing power even though the nominal value of the investment in monetary terms has increased.
Manager's risk	This risk refers to the day-to-day management of the target fund by Nomura which will impact the performance of the target fund, e.g. investment decisions undertaken by Nomura as a result of an incorrect view of the market or any non-compliance with internal policies, investment mandate, the deed, relevant law or guidelines due to factors such as human error or weakness in operational process and systems may adversely affect the performance of the target fund. In order to mitigate this risk, the implementation of internal controls and a structured investment process and operational procedures has been put in place by Nomura.
Concentration risk	As the target fund invests at least 80% of its NAV in the master fund, it is subject to concentration risk as the performance of the target fund would be dependent on the performance of the master fund.
Country risk	The investment of the target fund may be affected by risk specific to the country which it invests in. Such risks include changes in the country’s economic, social and political environment. The value of the assets of the target fund may also be affected by uncertainties such as currency repatriation restrictions or other developments in the law or regulations of the country which the target fund invests in, i.e. Ireland, the domicile country of the master fund.

RISKS (CONTINUED)	
Default risk	Default risk relates to the risk that an issuer of a money market instrument either defaulting on payments or failing to make payments in a timely manner which will in turn adversely affect the value of the money market instruments. This could affect the value of the target fund as up to 20% of the NAV of the target fund will be invested in liquid assets which include but are not limited to deposits and money market instruments.
Investment manager of the master fund risk	The target fund will invest in the master fund managed by a foreign asset management company. This risk refers to the risk associated with the investment manager, which include: i) The risk of non-adherence to the investment objective, strategy and policies of the master fund; ii) The risk of direct or indirect losses resulting from inadequate or failed operational and administrative processes and systems by the investment manager; and iii) The risk that the master fund may underperform its benchmark due to poor investment decisions by the investment manager.

Source : Nomura Asset Management Malaysia Sdn Bhd
Date : 29 August 2025

Disclaimer:
This is strictly the performance of the investment fund, and not the returns earned on the actual premiums paid of the investment-linked product. Past performance of the fund is not an indication of its future performance. The performance of the fund is not guaranteed. The value of the fund will fluctuate and may fall below the amount of premiums paid and the fund value depends on the actual performance of the underlying investment. This material is for information purposes only and is subject to change at any time without notice. Sun Life Malaysia does not guarantee its accuracy, completeness, correctness or timeliness for any purpose or reason. This information should not be considered as advice or recommendation in relation to your account or particular investment objectives, financial situation or needs. You may not revise, transform, or build upon this material without prior written consent of Sun Life Malaysia. Before acting on any information you should seek independent financial advice. Sun Life Malaysia may suspend the unit pricing and defer the payment of benefits, other than death and total and permanent disability benefits, subscription or redemption of units, switching of funds, under this contract for a reasonable period in exceptional circumstances, such as and including intervening events resulting in temporary closure of any stock exchange.